Scarica l'app Stockscreener
6.99
21.28%
-1.89
Dopo l'orario di chiusura:
6.95
-0.04
-0.57%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OCUL Giù?
Forum
Previsione
Ocular Therapeutix Inc Borsa (OCUL) Ultime notizie
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test - MedCity News
Ocular Therapeutix Shares Fall After Eye Disease Treatment Shows Superiority in Phase 3 Trial at Week 36 - marketscreener.com
Ocular Therapeutix (OCUL) Shares Drop Amid Clinical Study Results - GuruFocus
Ocular: "Buy" As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk - Fierce Pharma
Ocular claims a win with eye drug data even as shares sink - BioPharma Dive
Ocular Therapeutix (OCUL) Stock Drops Following SOL-1 Trial Results - GuruFocus
Ocular Therapeutix releases positive topline results from SOL-1 - Ophthalmology Times
Ocular eyes superiority claim after Axpaxli success in wet AMD study, but shares fall - FirstWord Pharma
Ocular Therapeutix’s wet AMD treatment shows superiority over aflibercept - Investing.com Nigeria
Promising Biotech Ocular Gets Price Target Update After Groundbreaking Therapy News - TheStreet Pro
Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment - Intellectia AI
Ocular Therapeutix Financial Results Disappoint Investors - StocksToTrade
Ocular Therapeutix Struggles After Missing Revenue Expectations - timothysykes.com
Ocular Therapeutix (OCUL) Drops 22% Despite Positive Trial Resul - GuruFocus
Ocular Therapeutix's AXPAXLI Meets Superiority Endpoint In Wet AMD Trial, But Stock Down - Nasdaq
Ocular drops after late-stage trial data for wet AMD therapy - Seeking Alpha
Ocular Therapeutix stock news: Why positive data led to a 25% drop - Investing.com Canada
Ocular Therapeutix (OCUL) Achieves Success in Phase 3 Trial for Wet AMD Treatment - GuruFocus
Ocular Therapeutix reports positive results from Sol-1 phase 3 superiority trial in wet AMD - marketscreener.com
Ocular Therapeutix stock tumbles after wet AMD trial results By Investing.com - Investing.com Canada
Ocular Therapeutix stock tumbles after wet AMD trial results - Investing.com UK
Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial - TradingView
Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial - statnews.com
OCUL: AXPAXLI demonstrated statistically significant superiority to aflibercept in wet AMD at Week 52 - TradingView
Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD - GlobeNewswire
Ocular Therapeutix stock jumps in premarket as SOL-1 wet AMD data nears - Bez Kabli
OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds - Stocktwits
Deep Track Capital, LP Reduces Stake in Ocular Therapeutix Inc - GuruFocus
Ocular Therapeutix Drug Shows Promise In Eye Disorder, But Falls Short of Investor Hopes - Bitget
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom - The Chronicle-Journal
Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data - FinancialContent
Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 - marketscreener.com
Ocular Therapeutix to Announce Topline Data from SOL-1 Phase 3 Trial for Wet AMD on February 17, 2026 - geneonline.com
Will Ocular Therapeutix Inc. benefit from geopolitical trendsTrade Risk Report & Long-Term Safe Investment Ideas - mfd.ru
Ocular Therapeutix to Host Webcast Presenting SOL-1 Data for AXPAXLI™ on February 17, 2026 - Quiver Quantitative
Ocular Therapeutix™ to Announce Topline Data for SOL-1 - GlobeNewswire
Ocular Therapeutix: Considering Their Phase 3 'Superiority' Trial's Prospect (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix Equity Grants Balance Growth Plans And Dilution Concerns - Yahoo Finance
Why It's Time To Keep A Close Eye On OCUL - RTTNews
Ocular Therapeutix (OCUL) Stock Analysis: A Biotech Gem With 171% Upside Potential - DirectorsTalk Interviews
How Investors Are Reacting To Ocular Therapeutix (OCUL) Revenue Miss And Widening 2025 Net Loss - Sahm
Bearish Setup: Is Ocular Therapeutix Inc gaining market shareDay Trade & Daily Stock Trend Reports - baoquankhu1.vn
Ocular Therapeutix Faces Declining Sales and Profitability Amid Market Sentiment Shift - Markets Mojo
Aug Closing: Will Ocular Therapeutix Inc stock hit new highs in YEARMarket Sentiment Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Illumina (ILMN) and Ocular Therapeutix (OCUL) - The Globe and Mail
Will Ocular Therapeutix Inc stock hit new highs in YEARWeekly Risk Summary & Safe Entry Point Identification - baoquankhu1.vn
Ocular Therapeutix (NASDAQ:OCUL) Raised to Hold at Wall Street Zen - MarketBeat
(OCUL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
RBC Capital reiterates Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
Assessing Ocular Therapeutix (OCUL) Valuation After Recent Share Price Volatility - Sahm
Ocular Therapeutix Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com South Africa
Regulatory Turbulence Threatens Ocular Therapeutix: FDA Disruptions and Global Delays Raise Approval and Funding Risks - TipRanks
Ocular Therapeutix Reports Fourth Quarter and Full Year 2025 Financials, Provides Business Highlights - VisionMonday.com
Decoding Ocular Therapeutix Inc (OCUL): A Strategic SWOT Insight - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates - Finviz
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 8.8% on Better-Than-Expected Earnings - MarketBeat
Ocular Q4 Revenue Declines; Phase 3 Wet AMD Trial Data Expected Later This Month - Nasdaq
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
4.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):